DaVita Inc. (NYSE:DVA – Get Rating) has been given an average rating of “Hold” by the eight brokerages that are covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $130.50.
DVA has been the topic of several research reports. Truist Financial cut their price objective on shares of DaVita from $125.00 to $110.00 in a research report on Friday, May 6th. StockNews.com lowered shares of DaVita from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 5th.
In related news, Director Paula A. Price sold 700 shares of the firm’s stock in a transaction dated Monday, February 14th. The shares were sold at an average price of $113.64, for a total transaction of $79,548.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.00% of the company’s stock.
Shares of DVA opened at $100.05 on Friday. DaVita has a 12 month low of $94.38 and a 12 month high of $136.48. The company has a 50-day moving average price of $112.64 and a two-hundred day moving average price of $110.10. The company has a quick ratio of 1.25, a current ratio of 1.29 and a debt-to-equity ratio of 8.53. The stock has a market cap of $9.46 billion, a price-to-earnings ratio of 11.91, a P/E/G ratio of 1.24 and a beta of 1.13.
DaVita (NYSE:DVA – Get Rating) last issued its quarterly earnings results on Thursday, May 5th. The company reported $1.61 earnings per share for the quarter, missing analysts’ consensus estimates of $1.85 by ($0.24). DaVita had a net margin of 7.78% and a return on equity of 78.24%. The company had revenue of $2.82 billion during the quarter, compared to analyst estimates of $2.89 billion. During the same period in the prior year, the business earned $2.09 EPS. The business’s revenue for the quarter was down .1% on a year-over-year basis. Equities research analysts expect that DaVita will post 7.79 EPS for the current fiscal year.
DaVita Company Profile (Get Rating)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
- Get a free copy of the StockNews.com research report on DaVita (DVA)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.